In the last trading session, 1.15 million shares of the Apogee Therapeutics Inc (NASDAQ:APGE) were traded, and its beta was 2.30. Most recently the company’s share price was $48.38, and it changed around -$0.69 or -1.41% from the last close, which brings the market valuation of the company to $2.83B. APGE currently trades at a discount to its 52-week high of $72.29, offering almost -49.42% off that amount. The share price’s 52-week low was $19.91, which indicates that the current value has risen by an impressive 58.85% since then. We note from Apogee Therapeutics Inc’s average daily trading volume that its 10-day average is 0.61 million shares, with the 3-month average coming to 447.34K.
Apogee Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended APGE as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Apogee Therapeutics Inc is expected to report earnings per share of -1.07 for the current quarter.
Apogee Therapeutics Inc (NASDAQ:APGE) trade information
Instantly APGE has showed a red trend with a performance of -1.41% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 53.62 on recent trading dayincreased the stock’s daily price by 9.77%. The company’s shares are currently up 73.16% year-to-date, but still up 4.58% over the last five days. On the other hand, Apogee Therapeutics Inc (NASDAQ:APGE) is -20.84% down in the 30-day period. We can see from the shorts that 6.62 million shares have been sold at a short interest cover period of 18.09 day(s).
The consensus price target as assigned by Wall Street analysts is $95, which translates to bulls needing to increase their stock price by 49.07% from its current value. Analyst projections state that APGE is forecast to be at a low of $95 and a high of $95.
Apogee Therapeutics Inc (APGE) estimates and forecasts
Apogee Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 11.96 percent over the past six months and at a 8.04% annual growth rate that is well below the industry average of 17.10%.
Forecasts for the next quarter put sales growth at 0.00%.
APGE Dividends
Apogee Therapeutics Inc’s next quarterly earnings report is expected to be released in January.
Apogee Therapeutics Inc (NASDAQ:APGE)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 11.66% of Apogee Therapeutics Inc shares, and 127.20% of them are in the hands of institutional investors. The stock currently has a share float of 143.99%.
